ErinoakKids is the largest Children’s Treatment Centre in Ontario, annually serving over 20,000 children and youth with a wide range of disabilities and special needs. It is one of the largest and most complex transfer payment agencies of the Ontario Ministry of Children, Community and Social Services (MCCSS), with 850 staff members and an annual operating budget exceeding $60 million.
ErinoakKids works closely with its funding Ministry and community partners, serving as Lead Agency responsible for the effective delivery of many innovative initiatives of MCCSS in the service of children and youth, across an expansive catchment area which includes Peel, Halton, Dufferin — and for some programs — Waterloo and Wellington. The organization meets and exceeds its targets in all areas, and has a strong reputation for collaboration and excellence in the service of its community.
The executive compensation strategy at ErinoakKids is designed to attract and retain high performing personnel focused on achieving the organization’s strategic priorities and goals. The Board of Directors sets the compensation of the President and CEO, which is tied to a comprehensive set of deliverables and associated performance metrics. The compensation of other leadership personnel is set by the President and CEO with Board input. It is similarly articulated and measured to ensure alignment of goals and their achievement at all levels of the organization.
ErinoakKids competitive market for personnel (whose majority are allied health professionals) is that of the Ontario Hospital Association Region 3. This market consists of 26 acute care and teaching hospitals in the Central, Toronto Central, Mississauga Halton, Central West and Central East Local Health Integration Networks. The ErinoakKids practice is to set compensation levels for all positions at the organization at the 50th percentile of this market.
ErinoakKids does not does not give perquisites to its staff and appointees in accordance with the Broader Public Sector Perquisites Directive.